Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (LLY 16.30%) stock is off to the races!This morning, the Indianapolis-based pharmaceutical giant announced that its new GLP-1 weight loss pill, orforglipron, has "demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful [ACHIEVE-1] Phase 3 trial."Lilly shares are up 14.2% in response to the ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like Ozempic.The mid-stage trial results announced on Thursday by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds — or 7.9% of their body weight — over a 26-week period.That outcome compares favorably to Novo Nordisk’s widely prescribed Ozempic, which helped diabetic patient ...

Eli Lilly & Co (NYSE:LLY) stock is headed for its best day since August 2023, last seen up 13.4% at $838.48 at last check, after the pharmaceutical giant reported positive results for a phase 3 trial of its weight-loss drug, orforglipron. The experimental pill resulted in weight loss of nearly 8% at the highest dose, and lowered blood sugar in patients with type 2 diabetes. Today's pop helped Eli Lilly stock fully recover from its early April bear gap, and has it back in positive territory for 2025. LLY was ...

Core Points - Eli Lilly and Company will announce its first-quarter 2025 financial results on May 1, 2025, and will hold a conference call to discuss the performance [1] - The conference call is scheduled to begin at 10 a.m. Eastern time, and a live webcast will be available on Lilly's website [2] - Lilly has been a pioneer in medical discoveries for nearly 150 years, focusing on various health challenges including diabetes care, obesity treatment, Alzheimer's disease, immune system disorders, and cancer management [3]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Insights - Eli Lilly's daily obesity pill, orforglipron, has successfully met its goals in late-stage trials, demonstrating effectiveness in lowering blood sugar and body weight for Type 2 diabetes patients while maintaining safety comparable to existing injections [1][2][9] Company Summary - The trial results for orforglipron are highly anticipated within the pharmaceutical industry, positioning Eli Lilly to potentially offer a needle-free alternative in the expanding weight loss and diabetes market [2] - The highest dose of orforglipron resulted in an average weight loss of 7.9%, approximately 16 pounds, after 40 weeks, with no observed plateau in weight loss by the study's conclusion [4] - Eli Lilly plans to file for regulatory approval for orforglipron for obesity by the end of 2024 and for diabetes in 2026, which could enhance patient access and address supply shortages of current injection therapies [10] Industry Summary - The market for GLP-1 medications is projected to exceed $150 billion annually by the early 2030s, with oral GLP-1s potentially accounting for $50 billion of that total [12] - Eli Lilly's orforglipron is positioned to capture a significant market share as it is approximately three years ahead of competitors in developing oral versions of GLP-1 medications [11] - Unlike existing GLP-1 medications, orforglipron is not a peptide medication, allowing for easier absorption and eliminating the need for dietary restrictions [13]

Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses The investigational once-daily oral pill reduced weight by an average 16.0 lbs (7.9%) at the highest dose in a key secondary endpoint The overall safety and tolerability profile of orforglipron in ACHIEVE-1 was consistent with injectable GLP-1 therapies   INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline ...

Core Viewpoint - Eli Lilly and Company is facing challenges due to global uncertainties and competitive dynamics, but it has strong growth prospects driven by its key products Mounjaro and Zepbound, alongside a robust pipeline of new drugs. Group 1: Stock Performance and Market Dynamics - Eli Lilly's shares have declined by 8.2% in the past month, largely due to global uncertainties from the tariff war and fears of a recession [1] - The stock has outperformed the industry, which has decreased by 4.1%, and the S&P 500 index [15][26] - Despite a 1.7% decline in stock price this year, Lilly's market cap exceeds $700 billion, reflecting a 420.3% increase over the past five years [26] Group 2: Product Performance and Sales Growth - Mounjaro and Zepbound generated combined sales of $16.5 billion in 2024, accounting for approximately 36% of total revenues [3] - Sales growth of Mounjaro and Zepbound was impacted by supply and channel dynamics in the second half of 2024, raising concerns about demand [4] - Lilly expects to launch Mounjaro in new international markets in 2025, which is anticipated to boost sales [6] Group 3: New Drug Approvals and Pipeline - The FDA approved Zepbound for a second indication, which is expected to drive sales higher [7] - Lilly has gained approvals for several new drugs, including Omvoh and Jaypirca, contributing significantly to top-line growth in 2024 [8] - The company is making rapid progress in its pipeline, with several mid to late-stage readouts expected in 2025 [9] Group 4: Competitive Landscape - The obesity market is projected to expand to $100 billion by 2030, with Lilly and Novo Nordisk currently dominating [10] - Several companies, including Amgen and Viking Therapeutics, are developing GLP-1-based candidates that could pose competition to Lilly's products [12] - Other pharmaceutical companies are also entering the obesity space, which may threaten Lilly's market position [14] Group 5: Financial Outlook and Shareholder Returns - Lilly expects revenues in the range of $58.0 billion to $61.0 billion in 2025, indicating a 32% year-over-year growth [27] - The company returned $3 billion to shareholders in 2024 through share repurchases and dividends, and has approved a new $15 billion stock buyback plan [29]

Some of us might be due for a windfall in the form of a $1,400 IRS payment. Today is Tax Day, and on top of that, the last day that you can apply to claim a recovery rebate credit for 2021.Confused? During the pandemic, the government sent out several rounds of stimulus checks. Seeing as how many Americans did not file for 2021 taxes — either due to low income or loss of labor, they did not file for this particular check — but they do qualify.If you’re not facing immediate and necessary expenses, putting th ...

Group 1 - Eli Lilly & Company (LLY) has shown a strong performance since being rated a 'buy' in June 2023 [1] - The company is recognized for its effective drug manufacturing capabilities [1] Group 2 - Crude Value Insights provides an investment service focused on oil and natural gas, emphasizing cash flow generation [2] - Subscribers have access to a stock model account, detailed cash flow analyses of exploration and production firms, and live sector discussions [2]